STEALTH BIOTHERAPEUTICS CORP (MITO) 0.32 0 (-1.36%)
0.32 0 (-1.36%)
US85789A1051 - ADR
Fundamental Rating
We assign a fundamental rating of 1 out of 10 to MITO. MITO was compared to 631 industry peers in the Biotechnology industry. Both the profitability and financial health of MITO have multiple concerns. MITO has a expensive valuation and it also scores bad on growth
Profitability
Profitability Rating
The profitability ratios for MITO are negative, so there is not much use analyzing them.
MITO has a Return On Assets of -143.50%. This is below the industry average of -44.83%. 89% of the industry peers outperform MITO.
MITO has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for MITO.
VS Industry
ROA (-143.5%) VS Industry: 11% outperformed.
-950.38
52.28
Valuation
Valuation Rating
MITO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MITO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Growth
Growth Rating
MITO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Based on estimates for the next 5 years, MITO will show a small growth in Earnings Per Share. The EPS will grow by 4.98% on average per year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 0% | 23.5% | 16.73% | 7.29% | 4.98% |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
MITO has a Current Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
MITO has a Quick Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
When comparing the Current Ratio of MITO to the average industry Current Ratio of 6.16, MITO is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.05, MITO is worse placed to pay its short term obligations than its industry peers.
MITO has a negative Debt to Equity ratio (-0.26), which implies it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
MITO has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for MITO.
VS Industry
Quick Ratio (3.68) VS Industry: 32% outperformed.
0.02
84.53
Current Ratio (3.68) VS Industry: 31% outperformed.
0.02
85.09
Dividend
Dividend Rating
MITO does not give a dividend.
STEALTH BIOTHERAPEUTICS CORP0.32
NASDAQ:MITO (11/15/2022, 7:00:01 PM)0 (-1.36%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-18 2022-11-18/bmo | Earnings (Next) | N/A N/A |
| Ins Owners | N/A | Inst Owners | 1.22% |
| Market Cap | 23.54M | Analysts | 82.86 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | N/A | P/B | N/A |
| EV/EBITDA | -0.07 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | 0% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 0% |
| EPS Next Y | 23.5% | EPS Next 2Y | 16.73% |
| EPS Next 3Y | 7.29% | EPS Next 5Y | 4.98% |
| Revenue growth 1Y | N/A | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | N/A |
| Revenue Next Year | N/A | Revenue Next 2Y | N/A |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| Current Ratio | 3.68 | Quick Ratio | 3.68 |
| Altman-Z | N/A | F-Score | 2 |
| Debt/Equity | -0.26 | WACC | N/A |
| ROIC/WACC | N/A | ||
| ROA | -143.5% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | N/A | OM | N/A |
| Asset Turnover | N/A | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA